新芝生物
(430685)
| 流通市值：8.95亿 | | | 总市值：14.95亿 |
| 流通股本：5479.11万 | | | 总股本：9151.60万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 32,661,264.97 | 168,092,009.31 | 108,698,472.95 | 66,875,602.43 |
| 营业收入 | 32,661,264.97 | 168,092,009.31 | 108,698,472.95 | 66,875,602.43 |
| 二、营业总成本 | 26,613,381.96 | 132,795,178.43 | 90,655,525.72 | 57,827,984.45 |
| 营业成本 | 12,009,120.34 | 64,652,854.66 | 40,868,995.03 | 25,317,549.2 |
| 税金及附加 | 502,673.84 | 2,345,238.14 | 1,138,768.81 | 656,119.26 |
| 销售费用 | 5,284,626.37 | 26,000,545.47 | 16,923,633.69 | 10,807,721.94 |
| 管理费用 | 5,523,560.17 | 23,863,703.1 | 19,064,108.49 | 12,552,523.48 |
| 研发费用 | 3,658,992.32 | 17,738,026.42 | 14,030,100.63 | 9,456,285.55 |
| 财务费用 | -365,591.08 | -1,805,189.36 | -1,370,080.93 | -962,214.98 |
| 其中:利息费用 | 35,331.88 | 186,244.42 | 148,495.44 | 108,584.99 |
| 其中:利息收入 | 336,645.82 | 1,973,190.46 | 1,492,288.54 | 1,039,144.55 |
| 加:公允价值变动收益 | 762,343.28 | 3,163,765.13 | 2,266,077.09 | 1,514,284.48 |
| 加:投资收益 | 651,636.68 | 2,752,930.97 | 2,121,489.2 | 1,729,814.67 |
| 资产处置收益 | -9,174.31 | 13,680,415.14 | 23,875.22 | 23,875.22 |
| 资产减值损失(新) | -375,171.49 | -1,804,158.47 | -1,304,297.58 | -674,725.81 |
| 信用减值损失(新) | 18,925.9 | -187,502.97 | -377,004.2 | 67,843.71 |
| 其他收益 | 1,789,123.48 | 6,464,302.4 | 5,262,788.33 | 3,147,674.95 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 8,885,566.55 | 59,366,583.08 | 26,035,875.29 | 14,856,385.2 |
| 加:营业外收入 | 45,253.19 | 1,009,708.79 | 1,009,706.17 | 1,006,844.77 |
| 减:营业外支出 | 723.39 | 569,560.8 | 196,966.36 | 157,494.11 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 8,930,096.35 | 59,806,731.07 | 26,848,615.1 | 15,705,735.86 |
| 减:所得税费用 | 1,047,870.65 | 8,159,700.9 | 2,752,158.94 | 1,211,022.64 |
| 六、净利润 | 7,882,225.7 | 51,647,030.17 | 24,096,456.16 | 14,494,713.22 |
| 持续经营净利润 | 7,882,225.7 | 51,647,030.17 | 24,096,456.16 | 14,494,713.22 |
| 归属于母公司股东的净利润 | 6,501,584.76 | 41,627,687.27 | 21,653,091.07 | 13,060,822.08 |
| 少数股东损益 | 1,380,640.94 | 10,019,342.9 | 2,443,365.09 | 1,433,891.14 |
| (一)基本每股收益 | 0.07 | 0.47 | 0.24 | 0.15 |
| (二)稀释每股收益 | 0.07 | 0.47 | 0.24 | 0.15 |
| 九、综合收益总额 | 7,882,225.7 | 51,647,030.17 | 24,096,456.16 | 14,494,713.22 |
| 归属于母公司股东的综合收益总额 | 6,501,584.76 | 41,627,687.27 | 21,653,091.07 | 13,060,822.08 |
| 归属于少数股东的综合收益总额 | 1,380,640.94 | 10,019,342.9 | 2,443,365.09 | 1,433,891.14 |
| 公告日期 | 2025-04-28 | 2025-04-21 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |